Steps before prequalification

I. BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Macleods Pharmaceuticals Limited submitted in 2016, an application for [TB326 trade name]¹ (TB326) to be assessed with the aim of including [TB326 trade name] in the list of prequalified medicinal products for the prevention and treatment of tuberculosis.

[TB326 trade name] was assessed according to the 'Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies' by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

Jun 2014	The manufacturer of the FPP was inspected for compliance with WHO requirements for GMP.
Jul 2014	The sites relevant for the bioequivalence study were inspected for compliance with WHO requirements for GLP and GCP.
Jan 2015	One manufacturer of the API was inspected for compliance with WHO requirements for GMP.
Mar 2016	During the meeting of the assessment team the safety and efficacy data were reviewed and further information was requested.
Mar & Apr 2016	During the meeting of the assessment team the quality data were reviewed and further information was requested.
Mar 2016	The company's response letter was received.
May 2016	The safety and efficacy data were reviewed and found to comply with the relevant WHO requirements.
May 2016	One manufacturer of the API was inspected for compliance with WHO requirements for GMP.
Jun 2016	The company's response letter was received.
Jul & Sep	During the meetings of the assessment team the additional quality data were reviewed and
2016	further information was requested.
Aug 2016	One manufacturer of the API was inspected for compliance with WHO requirements for GMP.
Nov 2016	The company's response letter was received.
Jan 2017	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Mar 2017	The company's response letter was received.
Mar 2017	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
May 2017	The company's response letter was received.
May 2017	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Jun 2017	The company's response letter was received.
Jul 2017	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Aug 2017	The company's response letter was received.
Sep & Nov	During the meetings of the assessment team the additional quality data were reviewed and
2017	further information was requested.
Jan 2018	The company's response letter was received.
Jan 2018	During the meeting of the assessment team the additional quality data were reviewed and
	further information was requested.
Feb 2018	The company's response letter was received.
Feb 2018	The quality data were reviewed and found to comply with the relevant
	WHO requirements.
Feb 2018	Product dossier accepted (quality assurance)
22 Feb 2018	[TB326 trade name] was included in the list of prequalified medicinal products.

II GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer Inspection status

Manufacturer of the finished product and responsible for batch release:

Macleods Pharmaceuticals Limited Block-N2 Village Theda Post Office Lodhimajra Tehsil Baddi District Solan Himachal Pradesh – 174101 India

Inspection status

The sites inspected were found to be in compliance with WHO requirements for GMP, GCP and GLP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

 $\underline{https://extranet.who.int/pqweb/medicines/prequalified-lists/finished-pharmaceutical-products}$